Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Koerbel

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Scientific Reports|May 21, 2025
Clinical and paraclinical features distinguish fatigue from depression-predominant phenotypes in multiple sclerosisYavor Yalachkov, Kimberly Koerbel, Johannes Gehrig, et al.
European Journal of Neurology|November 21, 2022
Brain-specific biomarkers in urine as a non-invasive approach to monitor neuronal and glial damageKonstantin Kohlhase, Franziska Frank, Christian Wilmes, et al.
Neurology|October 12, 2021
Role of S100B Serum Concentration as a Surrogate Outcome Parameter After Mechanical ThrombectomySebastian Luger, Kimberly Koerbel, Ariane Martinez Oeckel, et al.
Multiple Sclerosis and Related Disorders|May 3, 2024
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosisKimberly Koerbel, Michelle Maiworm, Martin Schaller-Paule, et al.
International Journal of Molecular Sciences|January 25, 2025
Exploring the Link Between Renal Function Fluctuations Within the Physiological Range and Serum/CSF Levels of NfL, GFAP, tTAU, and UCHL1Kimberly Koerbel, Yavor Yalachkov, Tabea Rotter, et al.
Journal of Neurology|January 15, 2025
BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patientsMichelle Maiworm, Kimberly Koerbel, Victoria Anschütz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2026
Neurofilament light chain as a surrogate candidate for disease activity in multiple sclerosis (LUMINOUS)-A meta-regression of randomized controlled trialsRoxanne Pretzsch, Sahla El Mahdaoui, Poljanka Johnson, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Scientific Reports|May 21, 2025
Clinical and paraclinical features distinguish fatigue from depression-predominant phenotypes in multiple sclerosisYavor Yalachkov, Kimberly Koerbel, Johannes Gehrig, et al.
European Journal of Neurology|November 21, 2022
Brain-specific biomarkers in urine as a non-invasive approach to monitor neuronal and glial damageKonstantin Kohlhase, Franziska Frank, Christian Wilmes, et al.
Neurology|October 12, 2021
Role of S100B Serum Concentration as a Surrogate Outcome Parameter After Mechanical ThrombectomySebastian Luger, Kimberly Koerbel, Ariane Martinez Oeckel, et al.
Multiple Sclerosis and Related Disorders|May 3, 2024
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosisKimberly Koerbel, Michelle Maiworm, Martin Schaller-Paule, et al.
International Journal of Molecular Sciences|January 25, 2025
Exploring the Link Between Renal Function Fluctuations Within the Physiological Range and Serum/CSF Levels of NfL, GFAP, tTAU, and UCHL1Kimberly Koerbel, Yavor Yalachkov, Tabea Rotter, et al.
Journal of Neurology|January 15, 2025
BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patientsMichelle Maiworm, Kimberly Koerbel, Victoria Anschütz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2026
Neurofilament light chain as a surrogate candidate for disease activity in multiple sclerosis (LUMINOUS)-A meta-regression of randomized controlled trialsRoxanne Pretzsch, Sahla El Mahdaoui, Poljanka Johnson, et al.
Pageof 1